靶向 CD33 膜近端 C2-set 结构域以改善 CAR-T 细胞治疗

Current CD33-targeted immunotherapies typically recognize the membrane-distal V-set domain of CD33.

Here, we show that decreasing the distance between T cell and leukemia cell membrane increases the efficacy of CD33 chimeric antigen receptor (CAR) T cells.

We therefore generated and optimized second-generation CAR constructs containing single-chain variable fragments from antibodies raised against the membrane-proximal C2-set domain, which bind CD33 regardless of whether the V-set domain is present (CD33 PAN antibodies). CD33 PAN CAR T cells resulted in efficient tumor clearance and improved survival of immunodeficient mice bearing human AML cell xenografts and, in an AML model with limited CD33 expression, forced escape of CD33 neg leukemia.

Compared to CD33 V-set CAR T cells, CD33 PAN CAR T cells showed greater in vitro and in vivo efficacy against several human AML cell lines with differing levels of CD33 without increased expression of exhaustion markers. CD33 PAN moieties were detected at a higher frequency on human leukemic stem cells, and CD33 PAN CAR T cells had greater in vitro efficacy against primary human AML cells.

Together, our studies demonstrate improved efficacy with CAR T cells binding CD33 close to the cell membrane, providing the rationale to investigate CD33 PAN CAR T cells further toward possible clinical application.